You are here

Unleashing HSCT with Next Generation Approaches

Hematopoietic stem cell transplantation (HSCT) is commonly used to treat leukemias and severe disorders of the blood and immune system; however, the extension of HSCT to many patients in need of transplant, or into various new areas of disease that might benefit, remains problematic. This vast, untapped potential results from inadequate sources of healthy, immune‐compatible stem cells for transplant, technological barriers to efficient engraftment, and the significant health risks associated with the HSCT procedure itself. Now, a new Perspective article published in STEM CELLS Translational Medicine elaborates on current limitations of HSCT and describes novel strategies to overcome them, including key innovations developed with support from the California Institute for Regenerative Medicine. The authors, from the labs of Sohel Talib and Kelly A. Shepard (California Institute for Regenerative Medicine, Oakland, California, USA) believe that addressing these challenges could greatly expand the feasibility and accessibility of HSCT to all who might benefit, and enable HSCT to serve as a leading paradigm for developing new stem cell-based therapies in the future.